Janpix develops monovalent small-molecule protein degraders targeting STAT transcription factors. Its lead molecule targets both STAT3 and STAT5, which are implicated in tumor proliferation, survival and drug resistance. The company has identified degraders that show potential in hematological and solid tumors and is focused on advancing preclinical programs into the clinic. Janpix plans to advance its first candidate into clinical development and to expand its pipeline of STAT3 and STAT5 degraders, with plans in various hematological cancers. The company was launched in 2017 following seed financing by Medicxi and is based in Cambridge, Mass. It closed a $10 million Series B financing to support these development plans.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2020